ReportWire

Tag: microfluidics

  • Microsoft claims a ‘breakthrough’ in AI chip cooling

    [ad_1]

    AI is an enormous energy drain, contributing to greenhouse gas emissions at a time when the planet desperately needs progress in the opposite direction. Although most of that comes from running GPUs, cooling them is another significant overhead. So, it’s worth noting when a company of Microsoft’s stature claims to have achieved a breakthrough in chip cooling.

    Microsoft’s new system is based on microfluidics, a method long pursued but hard to implement. The company claims its approach could lead to three times better cooling than current methods.

    Many data centers rely on cold plates to prevent GPUs from overheating. Although effective to a degree, the plates are separated from the heat source by several layers of material, which limits their performance. “If you’re still relying heavily on traditional cold plate technology [in five years], you’re stuck,” Microsoft program manager Sashi Majety is quoted as saying in the company’s announcement.

    In microfluidics, the coolant flows closer to the source. The liquid in Microsoft’s prototype moves through thread-like channels etched onto the back of the chip. The company also used AI to more efficiently direct the coolant through those channels.

    Another aspect separating this prototype from previous attempts is that it drew inspiration from Mother Nature. As you can see in the image above, the etchings resemble the veins in a leaf or a butterfly wing.

    Microsoft says the technique can reduce the maximum silicon temperature rise inside a GPU by 65 percent. (However, that number depends on the workload and chip type.) This would enable overclocking “without worrying about melting the chip down,” Microsoft’s Jim Kleewein said. It could allow the company to place servers closer together physically, reducing latency. It would also lead to “higher-quality” waste heat use.

    Although this sounds good for the environment in a general sense, Microsoft’s announcement doesn’t lean into that. The blog post primarily discusses the technique’s potential for performance and efficiency gains. Green benefits are only alluded to briefly as “sustainability” and reduced grid stress. Let’s hope that’s only a case of a cynical observer overanalyzing framing. Our planet needs all the help it can get.

    [ad_2]

    Will Shanklin

    Source link

  • Osteo-Pharma and Emultech Announce Joint Venture to Develop First-in-Class Disease-Modifying Treatment for Osteoarthritis

    Osteo-Pharma and Emultech Announce Joint Venture to Develop First-in-Class Disease-Modifying Treatment for Osteoarthritis

    [ad_1]

    Emultech and Osteo-Pharma today announced a joint venture, Bone-Tech, to develop what could be the first disease-modifying treatment for osteoarthritis of the knee. Bone-Tech brings together Osteo-Pharma’s novel combination drug therapy for the local treatment of osteoarthritis with Emultech’s world-leading microfluidics’ microspheres technology.  Bone-Tech’s patented OsteoActivator™ microspheres treatment promises to be the first and only extended-release treatment targeting subchondral bone remodelling for patients suffering from osteoarthritis-related pain and disability.

    Osteoarthritis (OA), the most common form of arthritis, is a chronic, degenerative disease affecting over 1.5 billion people globally. OA causes life-long pain and is a leading cause of disability in the US and worldwide, accounting for >$185 billion in annual costs in the US alone in 2016. In OA patients, subchondral bone is characterized by impaired bone remodelling and the presence of bone marrow lesions (BML). BML’s are a hallmark in OA diagnosis and are strongly associated with pain, are a prognostic marker for cartilage loss and are predictive for the need for knee replacement surgery.

    “Intraosseous injection of OsteoActivator™ microspheres directly into subchondral bone locally targets osteoblast and osteoclast cells to restore bone remodelling, improves bone quality and relieves pain. There are currently no disease modifying treatments in the OA therapies market, and as such, OsteoActivator™ microspheres will be the first of its kind”, said Jan Gossen, CEO of Osteo-Pharma.

    “With its extended-release microsphere formulation, we believe the Bone-Tech product holds the potential to disrupt the current treatment paradigm, and we are dedicated to bringing this important new therapy to market for the millions of patients confronting this relentless disease”, said Rene Hansen, CEO of Emultech.

    Bone-Tech’s novel approach has demonstrated proof-of-concept in in-vitro and animal studies and is under development in preparation for IND filing and first-in-man studies. The Bone-Tech product employs proprietary microsphere technology for the extended-release of a combination of two well-known therapeutic agents delivered via intraosseous injection. Bone-Tech plans to pursue a rapid and low risk 505(b)(2) strategy to progress the product through clinical trials.   

    Bone-Tech is actively seeking venture and/or strategic partners to support clinical development. If interested, please contact Bone-Tech using the contact information below. 

    About Osteo-Pharma

    Osteo-Pharma is a Life Sciences company developing novel medical devices and pharmaceuticals to improve the local healing of bone defects and fractures. Its proprietary OsteoActivator platform is currently used to develop products for both dental and orthopedic applications. The company has recently announced its MREC approval for the initiation of a clinical trial for their lead product, OsteoActivator-P, in patients.

    About Emultech

    Emultech has developed the first and only continuous production of microparticles based on microfluidics. Emultech’s system enables superior control of particle properties (monodispersity, size, circularity and morphology) with high encapsulation efficiency, resulting in improved and adjustable loading, controlled drug release and degradation profiles with easier injectability. Our process is low energy and safe for all molecules, and parallelization enables instant, low risk, scale-up for high throughput production that is suitable for GMP. 

    Press Contact: 

    Scott Fleming, CCO, Emultech BV   scott.fleming@emultech.nl   +31 6 46 87 69 89

    Other Contact:

    Jan Gossen, CEO, Osteo-Pharma BV  info@osteo-pharma.com 

    Source: Bone-Tech

    [ad_2]

    Source link